| Molecule | Cat. No. | Product Name | Species | Host | Structure | Purity | Activity | Size&Price | Add to Cart |
|---|---|---|---|---|---|---|---|---|---|
| HLA-A*0201 & B2M & HBV (FLLTRILTI) | Biotinylated Human HLA-A*02:01&B2M&HBV (FLLTRILTI) Complex Protein (Monomer, MALS verified) |  Human | HEK293 | MALSSDS-PAGE | $125.00 25ug |   | |||
| HLA-A*0201 & B2M & HBV (FLLTRILTI) | PE-Labeled Human HLA-A*02:01&B2M&HBV (FLLTRILTI) Tetramer Protein | Human | HEK293 | $410.00 25ug | |
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| GRN Gene Therapy（Eli Lilly And Company） | PR-006 | Phase 2 Clinical | Eli Lilly And Company | Frontotemporal Dementia | Details |
| TAK-594 | DNL-593; PTV:PGRN; TAK-594 | Phase 2 Clinical | Denali Therapeutics Inc | Frontotemporal Dementia | Details |
| AVB-101 | AVB-101 | Phase 2 Clinical | AviadoBio Ltd | Frontotemporal Dementia | Details |
| AL-101 | GSK-4527226; AL-101 | Phase 2 Clinical | Alector Inc | Nerve Degeneration; Alzheimer Disease; Parkinson Disease; Frontotemporal Dementia; Amyotrophic Lateral Sclerosis | Details |
| PBFT-02 | PBFT-02 | Phase 2 Clinical | Passage Bio Inc | Frontotemporal Dementia | Details |
| AG-01（A&G Pharm） | AG-01（A&G Pharm） | Phase 1 Clinical | A&G Pharmaceutical | Triple Negative Breast Neoplasms; Mesothelioma; Carcinoma, Non-Small-Cell Lung | Details |
